Understanding Ozempic and Gastroparesis: Testing and Evaluation in Texas

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Legal Concerns

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about gastroparesis. This concern has grown as more patients and doctors report delayed stomach emptying linked to GLP-1 medications. Building on decades of general health education that emphasized medication safety, this page reviews current reports on Ozempic-associated gastroparesis and outlines the testing and evaluation process in Texas.

The Medical Link Between Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Its pharmacological action slows gastric emptying, a mechanism that can, in susceptible individuals, progress to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis often includes postprandial fullness, bloating, and severe nausea, which can be debilitating and lead to malnutrition, dehydration, and hospitalizations. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, confirming delayed emptying. The link between Ozempic and gastroparesis is grounded in its mechanism of action. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, effects that are intended to reduce postprandial glucose excursions. However, in some patients, this delay becomes pathological, resulting in gastroparesis. The FDA-approved labeling for Ozempic documents gastrointestinal adverse reactions at significantly higher rates than placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, compared to 32.7% for Ozempic 0.5 mg and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to these reactions was also higher: 3.1% for 0.5 mg and 3.8% for 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal reactions reported at frequencies below 5% include dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these are not explicitly labeled as gastroparesis, they are consistent with its symptoms and reflect the drug's effect on gastric motility.

Mechanistic Pathways and Postmarketing Evidence

Mechanistic pathways linking Ozempic to gastroparesis involve prolonged inhibition of gastric emptying, which can lead to gastric stasis, bezoar formation, and vagal nerve dysfunction. Postmarketing reports have raised concerns about retained gastric contents even after preoperative fasting, as noted in warnings for GLP-1 receptor agonists: "There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for severe gastroparesis-like effects, as residual gastric contents indicate delayed emptying. Regarding risk anchors, the adequacy of warnings for Ozempic and gastroparesis is a critical issue. The current labeling does not explicitly list gastroparesis as a warning or adverse reaction, instead grouping it under general gastrointestinal effects. This may leave patients and clinicians unaware of the risk, especially given that symptoms like nausea and vomiting are common and often dismissed as transient. The lack of a specific warning could delay diagnosis and treatment, allowing harm to progress.

Statute of Limitations for Ozempic Claims in Texas

For affected patients in Texas, attorney-related considerations include the statute of limitations for product liability claims. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For Ozempic-related gastroparesis, this timeline begins when a patient is diagnosed or when symptoms become severe enough to link to the drug. Given that gastroparesis can develop insidiously over months of Ozempic use, patients may not immediately connect their symptoms to the medication. The timeline between exposure and documented harm is thus crucial: patients may have taken Ozempic for weeks or months before experiencing severe nausea, vomiting, or abdominal pain, and diagnosis may require specialist evaluation. This delay can compress the statute of limitations window, making prompt legal consultation essential. In summary, the evidence supports a plausible link between Ozempic and gastroparesis through its pharmacological effects on gastric emptying, with clinical trial data showing elevated gastrointestinal adverse reactions and postmarketing reports of retained gastric contents. The adequacy of warnings is questionable, as gastroparesis is not explicitly highlighted. Texas patients who develop gastroparesis after Ozempic use should be aware of the two-year statute of limitations from discovery of injury and should seek legal advice to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Texas?

In Texas, the statute of limitations for personal injury claims, including product liability for Ozempic-related gastroparesis, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. This means the clock starts when a patient is diagnosed with gastroparesis or when symptoms become severe enough to link to Ozempic. Because gastroparesis can develop gradually, patients may not realize the connection immediately, so it is crucial to consult an attorney promptly to avoid missing the deadline.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism to control blood sugar. In some individuals, this delay becomes pathological, leading to gastroparesis—a condition where the stomach empties too slowly without a physical blockage. Symptoms include nausea, vomiting, early satiety, and abdominal pain. Clinical trials show significantly higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), and postmarketing reports have noted retained gastric contents even after fasting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.